EUVIMEDEUVIMED entdecken
Crossref

The effect of nirmatrelvir‐ritonavir on the long‐term risk of neuropsychiatric sequelae following COVID‐19

Ting-Hui Liu, Jheng-Yan Wu iD, Po-Yu Huang iD, Ya-Wen Tsai iD, Chih-Cheng Lai iD

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Ting-Hui Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: COVID-19, Sleep Initiation and Maintenance Disorders, Dementia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The retrospective cohort was conducted to assess the effect of nirmatrelvir‐ritonavir (NMV‐r) on the long‐term risk of neuropsychiatric sequela following COVID‐19. TriNetX research network was used to identify nonhospitalized adult patients who tested positive for severe acute respiratory syndrome coronavirus 2 infection or were diagnosed with COVID‐19 between March 1, 2020 and July 1, 2022. Further propensity score matching method was used to create two matched cohorts with and without receiving NMV‐r. The primary outcome was the incidence of neuropsychiatric sequela within a 90‐day to 1‐year period following a diagnosis of COVID‐19. After screening 119 494 527 electronic health records, two matched cohorts of each 27 194 patients were identified. During the follow‐up period, the NMV‐r group demonstrated a reduced risk of any neuropsychiatric sequelae compared to the control group (odds ratio [OR], 0.634; 95% confidence interval [CI], 0.604−0.667). In comparison with the control group, the patient treated with NMV‐r exhibited a markedly diminished risk of developing neurocognitive sequela (OR, 0.377; 95% CI, 0.325−0.439) and psychiatric sequela (OR, 0.629; 95% CI, 0.593−0.666). In addition, patients treated with NMV‐r had a significantly reduced risk of developing dementia (OR, 0.365; 95% CI, 0.255−0.522), depression (OR, 0.555; 95% CI, 0.503−0.612), insomnia (OR, 0.582; 95% CI, 0.508−0.668) and anxiety disorder (OR, 0.645 95% CI, 0.600−0.692). Moreover, the beneficial effect of NMV‐r on the neuropsychiatric sequelae was observed across further subgroup analyses. Among nonhospitalized COVID‐19 patients, who at risk of disease progression, the use of NMV‐r is associated with a reduction in the long‐term risk of neuropsychiatric sequela, including dementia, depression, insomnia and anxiety disorder. It may be necessary to re‐evaluate the use of NMV‐r, as a preventive measure to reduce the risk of severe acute disease and post‐acute adverse mental health outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Sleep Initiation and Maintenance DisordersDementiaAdultHumansCOVID-19 Drug TreatmentRetrospective StudiesRitonavirDisease ProgressionAntiviral AgentsLactamsLeucineNitrilesProline

Stichwörter der Autor:innen

COVID-19SARS-CoV-2neurologicnirmatrelvir-ritonavirpsychiatric

Substanzen

RitonavirAntiviral AgentsnirmatrelvirLactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Department of Psychiatry, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Center of Integrative Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Division of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.

ORCID-Profile: Jheng-Yan Wu, Po-Yu Huang, Ya-Wen Tsai, Chih-Cheng Lai

Zitieren

APA

Liu, T. H., Wu, J. Y., Huang, P. Y., Tsai, Y. W., & Lai, C. C. (2023). The effect of nirmatrelvir‐ritonavir on the long‐term risk of neuropsychiatric sequelae following COVID‐19. Journal of Medical Virology. https://doi.org/10.1002/jmv.28951

Vancouver

Liu TH, Wu JY, Huang PY, Tsai YW, Lai CC. The effect of nirmatrelvir‐ritonavir on the long‐term risk of neuropsychiatric sequelae following COVID‐19. Journal of Medical Virology. 2023. doi:10.1002/jmv.28951

BibTeX
@article{Liu2023,
  author = {Liu, Ting-Hui and Wu, Jheng-Yan and Huang, Po-Yu and Tsai, Ya-Wen and Lai, Chih-Cheng},
  title = {The effect of nirmatrelvir‐ritonavir on the long‐term risk of neuropsychiatric sequelae following COVID‐19},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28951}
}
Kostenlos starten →